Skip to main content
Show full summary

Baroness Finlay of Llandaff to ask His Majesty's Government what assessment they have made of the negative impact on pharmaceutical research investment in the UK of the refusal by National Institute for Health and Care Excellence to approve tofersen for SOD-1 MND patients in the UK.  HL3732

Question HL3732: tabled on 15 April 2024 and due for answer by 29 April 2024

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

Baroness Finlay of Llandaff to ask His Majesty's Government what assessment they have made of the negative impact on pharmaceutical research investment in the UK of the refusal by National Institute for Health and Care Excellence to approve tofersen for SOD-1 MND patients in the UK.  HL3732
Legend for business item text
Item that is new or altered.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.